Brief: Hansa Biopharma, Medison Pharma Announce Positive Reimbursement Decision In Poland
22/08/2022 15:25
Aug 22 (Reuters) - Hansa Biopharma AB HNSA.ST :
* HANSA BIOPHARMA AND MEDISON PHARMA ANNOUNCE POSITIVE
REIMBURSEMENT DECISION IN POLAND FOR IDEFIRIX® IN HIGHLY
SENSITIZED KIDNEY TRANSPLANT PATIENTS
* REIMBURSEMENT DECISION PROVIDES HIGHLY SENSITIZED PATIENTS
IN
POLAND ACCESS TO IDEFIRIX TO ENABLE KIDNEY TRANSPLANTATION FROM
SEPTEMBER 1ST, 2022
Source text for Eikon: ID:nWkr5G0Q3z
Further company coverage: HNSA.ST
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS